AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,653 | +4.2% | 16,188 | +19.2% | 0.00% | – |
| Q2 2023 | $384,557 | +17.0% | 13,579 | -5.1% | 0.00% | – |
| Q1 2023 | $328,746 | -1.7% | 14,312 | +20.1% | 0.00% | – |
| Q4 2022 | $334,489 | -51.3% | 11,912 | -51.0% | 0.00% | -100.0% |
| Q3 2022 | $687,000 | -27.8% | 24,291 | -43.4% | 0.00% | 0.0% |
| Q2 2022 | $951,000 | -54.4% | 42,915 | -40.1% | 0.00% | 0.0% |
| Q1 2022 | $2,087,000 | -37.0% | 71,693 | -28.9% | 0.00% | -50.0% |
| Q4 2021 | $3,314,000 | -35.8% | 100,819 | -9.9% | 0.00% | -33.3% |
| Q3 2021 | $5,163,000 | -19.6% | 111,873 | -4.0% | 0.00% | -25.0% |
| Q2 2021 | $6,423,000 | +17.1% | 116,543 | +9.7% | 0.00% | 0.0% |
| Q1 2021 | $5,486,000 | +37.6% | 106,223 | +15.5% | 0.00% | +33.3% |
| Q4 2020 | $3,986,000 | +683.1% | 92,001 | +533.0% | 0.00% | – |
| Q3 2020 | $509,000 | -53.1% | 14,535 | -28.5% | 0.00% | -100.0% |
| Q2 2020 | $1,086,000 | +103.8% | 20,320 | +35.3% | 0.00% | 0.0% |
| Q1 2020 | $533,000 | -17.1% | 15,018 | +11.6% | 0.00% | 0.0% |
| Q4 2019 | $643,000 | +119.5% | 13,453 | +48.5% | 0.00% | – |
| Q3 2019 | $293,000 | -56.3% | 9,057 | -32.7% | 0.00% | -100.0% |
| Q2 2019 | $671,000 | -33.3% | 13,452 | -9.9% | 0.00% | 0.0% |
| Q1 2019 | $1,006,000 | +58.9% | 14,925 | +8.7% | 0.00% | 0.0% |
| Q4 2018 | $633,000 | -48.3% | 13,731 | -13.5% | 0.00% | 0.0% |
| Q3 2018 | $1,225,000 | -4.7% | 15,881 | +4.2% | 0.00% | 0.0% |
| Q2 2018 | $1,285,000 | +5.5% | 15,248 | +2.4% | 0.00% | 0.0% |
| Q1 2018 | $1,218,000 | +59.4% | 14,895 | +11.5% | 0.00% | 0.0% |
| Q4 2017 | $764,000 | +101.6% | 13,362 | +135.1% | 0.00% | – |
| Q3 2017 | $379,000 | +4.1% | 5,683 | -19.8% | 0.00% | – |
| Q2 2017 | $364,000 | +17.8% | 7,083 | +33.8% | 0.00% | – |
| Q1 2017 | $309,000 | +30.9% | 5,294 | -6.2% | 0.00% | – |
| Q4 2016 | $236,000 | -25.1% | 5,645 | -5.2% | 0.00% | – |
| Q3 2016 | $315,000 | +26.0% | 5,956 | 0.0% | 0.00% | – |
| Q2 2016 | $250,000 | -16.9% | 5,956 | +28.5% | 0.00% | – |
| Q4 2015 | $301,000 | -8.8% | 4,635 | -0.7% | 0.00% | -100.0% |
| Q3 2015 | $330,000 | +28.9% | 4,668 | +72.1% | 0.00% | – |
| Q1 2015 | $256,000 | +4.9% | 2,713 | +24.3% | 0.00% | – |
| Q4 2014 | $244,000 | -11.9% | 2,182 | -51.8% | 0.00% | – |
| Q3 2014 | $277,000 | -82.7% | 4,523 | -89.0% | 0.00% | -100.0% |
| Q1 2014 | $1,605,000 | +65.1% | 41,000 | +1.0% | 0.00% | +50.0% |
| Q4 2013 | $972,000 | -13.1% | 40,600 | +1.5% | 0.00% | 0.0% |
| Q3 2013 | $1,118,000 | – | 40,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |